Ó³»­´«Ã½

Mary Lynne is a senior scientific fellow at the Ó³»­´«Ã½ of MIT and Harvard, where she serves as a strategic advisor to scientists across the institute, and a venture partner at Third Rock Ventures. She sits on the boards of Eli Lilly, Veeva, Centessa, and WITH (Women Innovating Together in Healthcare), and is chair of the Life Science Committee at the Boston Museum of Science. She is an active participant in the Biotech CEO sisterhood and serves as an advisor to several biotech CEOs. 

Most recently, Hedley was co-founder, director, president, and COO/CSO of TESARO, a biotechnology company focused on the development and global commercialization of medicines to treat patients living with cancer. She oversaw a team responsible for R&D, global manufacturing and operations, portfolio management, commercial development, business development, and corporate strategy. Prior to its acquisition by GSK for $5.1 billion, over 8 years TESARO had built a robust pipeline of products and drug candidates, had received multiple drug approvals, was commercializing medicines in the US and Europe, and was recognized for its productivity and creative drug development strategies. Notable successes were the development of the PARP inhibitor Zejula, which changed the treatment paradigm for women diagnosed with ovarian cancer, and the approval of dostarlimab in first line endometrial cancer and its development in first line MSI-H rectal cancer. Prior to founding TESARO, Hedley served as CSO and EVP of operations at Abraxis prior to its acquisition by Celgene and EVP of Eisai Inc, a role she assumed following the acquisition in January 2008, of MGI PHARMA by Eisai for $3.9 billion. At MGI, Hedley was EVP & CSO, responsible for R&D. Prior to her role at MGI, she was a co-founder of ZYCOS Inc., where she served as a director, president, and CEO prior to the acquisition of ZYCOS by MGI PHARMA in 2004.
 
Hedley is an immunologist by training and graduated with a B.S. with honors in Microbiology from Purdue University and a Ph.D. in molecular and cellular immunology from UT Southwestern Medical Center. She did her postdoctoral training at Harvard University in the areas of immunology and gene regulation with Tom Maniatis and Jack Strominger.